溃疡性结肠炎患儿中与维得利珠单抗相关的肺部表现。
Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis.
机构信息
Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
出版信息
J Clin Pharm Ther. 2022 Feb;47(2):254-256. doi: 10.1111/jcpt.13494. Epub 2021 Jul 18.
WHAT IS KNOWN AND OBJECTIVE
The off-label use of vedolizumab (VDZ) for inflammatory bowel disease in children is increasing. We report on possibly the first case of VDZ-associated pulmonary manifestations in paediatrics.
CASE SUMMARY
This report details the case of a 13-year-old child with ulcerative colitis who was initiated on VDZ due to persistent active disease. After the first three doses, he developed a persistent and productive cough. Microbiological work-up was normal. VDZ discontinuation led to the resolution of symptoms.
WHAT IS NEW AND CONCLUSION
To our knowledge, this is the first case report of VDZ-associated pulmonary manifestations in paediatrics. A direct, pro-inflammatory effect of VDZ has been hypothesized, but further studies are warranted.
已知和目的
vedolizumab（VDZ）在儿童中的非适应证使用用于炎症性肠病的情况正在增加。我们报告儿科中可能首例与 VDZ 相关的肺部表现的病例。
病例总结
本报告详细介绍了一例溃疡性结肠炎患儿的病例，该患儿因疾病持续活动而开始接受 VDZ 治疗。在接受前三剂治疗后，他出现了持续和多痰的咳嗽。微生物学检查结果正常。停用 VDZ 后症状得到缓解。
重要信息和结论
据我们所知，这是儿科中首例与 VDZ 相关的肺部表现的病例报告。已假设 VDZ 具有直接的促炎作用，但需要进一步的研究。
Zotero 插件